{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:06:03Z","timestamp":1780513563644,"version":"3.54.1"},"reference-count":120,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.09.008","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T16:32:24Z","timestamp":1757608344000},"page":"e141-e156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions | Incorporating Immunotherapy into Upfront Acute Lymphoblastic Leukemia Therapy"],"prefix":"10.1016","volume":"26","author":[{"given":"Ajoy L.","family":"Dias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 5","key":"10.1016\/j.clml.2025.09.008_bib0001","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.clml.2025.09.008_bib0002","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980:SEER analysis","volume":"129","author":"Geyer","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.09.008_bib0003","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/asheducation-2016.1.573","article-title":"Treatment of older patients with acute lymphoblastic leukemia","volume":"2016","author":"Gokbuget","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.clml.2025.09.008_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030565","article-title":"Characteristics and outcome of elderly patients (>55 Years) with acute lymphoblastic leukemia","volume":"14","author":"Wenge","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.clml.2025.09.008_bib0005","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clml.2025.09.008_bib0006","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2025.09.008_bib0007","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/10428194.2010.529206","article-title":"Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia","volume":"52","author":"Piccaluga","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2025.09.008_bib0008","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5 Suppl 14","key":"10.1016\/j.clml.2025.09.008_bib0009","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-Lopez","year":"1999","journal-title":"Semin Oncol"},{"issue":"25","key":"10.1016\/j.clml.2025.09.008_bib0010","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.09.008_bib0011","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2009.010306","article-title":"Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"95","author":"Maury","year":"2010","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2025.09.008_bib0012","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult burkitt and burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.clml.2025.09.008_bib0013","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2025.09.008_bib0014","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood.V116.21.170.170","article-title":"Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+B-lineage standard and high risk patients; results of 263 CD20+patients studied prospectively in GMALL study 07\/2003","volume":"116","author":"Hoelzer","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.09.008_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.blre.2011.08.001","article-title":"Chemoimmunotherapy in acute lymphoblastic leukemia","volume":"26","author":"Hoelzer","year":"2012","journal-title":"Blood Rev"},{"issue":"11","key":"10.1016\/j.clml.2025.09.008_bib0016","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2025.09.008_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00038-2","article-title":"Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial","volume":"9","author":"Marks","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.008_bib0018","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.clml.2025.09.008_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30144-7","article-title":"Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial","volume":"7","author":"Jabbour","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.09.008_bib0020","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/blood-2019-129884","article-title":"Phase II study of the Hyper-CVAD regimen in combination with Ofatumumab (HCVAD-O) As frontline therapy for adult patients (pts) with CD20-positive B-cell acute lymphoblastic leukemia (B-ALL)","volume":"134","author":"Richard-Carpentier","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.09.008_bib0021","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.clml.2025.09.008_bib0022","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clml.2025.09.008_bib0023","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clml.2025.09.008_bib0024","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","article-title":"FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease","volume":"25","author":"Jen","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.clml.2025.09.008_bib0025","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1634\/theoncologist.2018-0179","article-title":"FDA supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia","volume":"23","author":"Pulte","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2025.09.008_bib0026","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clml.2025.09.008_bib0027","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.32558","article-title":"Blinatumomab compared with standard of care for the treatment of adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia","volume":"126","author":"Rambaldi","year":"2020","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.clml.2025.09.008_bib0028","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.09.008_bib0029","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-022-00766-7","article-title":"Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study","volume":"13","author":"Boissel","year":"2023","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.clml.2025.09.008_bib0030","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3324\/haematol.2021.280078","article-title":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL","volume":"107","author":"Cabannes-Hamy","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2025.09.008_bib0031","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/cncr.34667","article-title":"Low leukemia burden improves blinatumomab efficacy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"129","author":"Queudeville","year":"2023","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2025.09.008_bib0032","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.09.008_bib0033","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","article-title":"Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab","volume":"8","author":"Kohnke","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.008_bib0034","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2147\/PROM.S149420","article-title":"Impact of blinatumomab on patient outcomes in relapsed\/refractory acute lymphoblastic leukemia: evidence to date","volume":"9","author":"Hathaway","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"issue":"4","key":"10.1016\/j.clml.2025.09.008_bib0036","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ajh.27227","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2025.09.008_bib0037","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/bloodadvances.2020002439","article-title":"Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia","volume":"5","author":"Advani","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2025.09.008_bib0038","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2012.01.001","article-title":"The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia","volume":"26","author":"Moorman","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2025.09.008_bib0039","article-title":"Preliminary results of the GIMEMA LAL 2317 sequential chemotherapy- blinatumomab front- line trial for newly diagnosed adult ph-negative B- lineage ALL patients","author":"Bassan","year":"2021","journal-title":"EHA library"},{"key":"10.1016\/j.clml.2025.09.008_bib0040","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood-2023-174973","article-title":"Sequential chemotherapy and blinatumomab to improve minimal residual disease in adult ph-B-lineage acute lymphoblastic leukemia. Final results of the phase II Gimema LAL 2317 trial","volume":"142","author":"Chiaretti","year":"2023","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2025.09.008_bib0041","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1182\/blood.2024027500","article-title":"Up-front blinatumomab improves MRD clearance and outcome in adult ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study","volume":"145","author":"Bassan","year":"2025","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2025.09.008_bib0042","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0043","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2021-146163","article-title":"Frontline consolidation with blinatumomab for high-risk Philadelphia-negative acute lymphoblastic adult patients. Early results from the Graall-2014-QUEST phase 2","volume":"138","author":"Boissel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0044","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood-2021-151826","article-title":"Sequential blinatumomab with reduced intensity chemotherapy in the treatment of older adults with newly diagnosed ph negative B-precursor acute lymphoblastic leukemia- interim analysis of the Australasian leukemia and lymphoma group ALL08 study","volume":"138","author":"Fleming","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.09.008_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00285-X","article-title":"Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial","volume":"9","author":"Jabbour","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.09.008_bib0046","article-title":"A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL)","volume":"41","author":"Short","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.09.008_bib0047","unstructured":"FDA, FDA approves Blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. 2024. Accessed June 14, 2024. https:\/\/www.prnewswire.com\/news-releases\/fda-approves-blincyto-blinatumomab-in-cd19-positive-philadelphia-chromosome-negative-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-in-the-consolidation-phase-302173376.html."},{"issue":"4","key":"10.1016\/j.clml.2025.09.008_bib0048","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.09.008_bib0049","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.09.008_bib0050","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.clml.2025.09.008_bib0051","article-title":"S115:consolidation with blinatumomab improves overall and relapse-free survival in patients with newly diagnosed B-cell acute lymphoblastic leukemia: impact of age and MRD level in ECOG-ACRIN E1910","volume":"7","author":"Litzow","year":"2023","journal-title":"Hemasphere"},{"issue":"9","key":"10.1016\/j.clml.2025.09.008_bib0052","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clml.2025.09.008_bib0053","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1002\/cncr.32139","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2025.09.008_bib0054","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/cncr.23819","article-title":"Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.clml.2025.09.008_bib0055","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.09.008_bib0056","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.09.008_bib0057","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-138569","article-title":"Reduced-intensity chemotherapy with Mini-Hyper-CVD plus inotuzumab ozogamicin with or without blinatumomab, in older adults with newly diagnosed Philadelphia chromosome- negative acute lymphoblastic leukemia: results from a phase II study","volume":"136","author":"Short","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0058","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2023-180472","article-title":"Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with ph\/BCR::ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial","volume":"142","author":"Goekbuget","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0059","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1182\/blood-2021-146214","article-title":"Dose-reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with B-precursor adult lymphoblastic leukemia (ALL): results of the ongoing GMALL bold trial","volume":"138","author":"Goekbuget","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0060","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2023.41.16_suppl.7006","article-title":"Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, ph-negative, CD22- positive, B-cell acute lymphoblastic leukemia: alliance A041703","volume":"41","author":"Wieduwilt","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.09.008_bib0061","first-page":"S117","article-title":"Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, ph-negative, cd22-positive, B-cell acute lymphoblastic leukemia: ALLIANCE A041703","volume":"387817","author":"Wieduwilt","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2025.09.008_bib0062","doi-asserted-by":"crossref","first-page":"6134","DOI":"10.1182\/blood-2022-156080","volume":"140","author":"Jabbour","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0063","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3389\/fimmu.2018.02235","article-title":"CD22: a regulator of innate and adaptive B cell responses and autoimmunity","volume":"9","author":"Clark","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.clml.2025.09.008_bib0064","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0065","first-page":"96","article-title":"Regulation of B cell functions by the sialic acid-binding receptors siglec-G and CD22","volume":"2","author":"Jellusova","year":"2011","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.clml.2025.09.008_bib0066","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1084\/jem.20011796","article-title":"Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling","volume":"195","author":"Jin","year":"2002","journal-title":"J Exp Med"},{"issue":"30","key":"10.1016\/j.clml.2025.09.008_bib0067","doi-asserted-by":"crossref","first-page":"12402","DOI":"10.1073\/pnas.1304888110","article-title":"CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling","volume":"110","author":"Muller","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2025.09.008_bib0068","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.immunol.15.1.481","article-title":"CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling","volume":"15","author":"Tedder","year":"1997","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"10.1016\/j.clml.2025.09.008_bib0069","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.09.008_bib0070","doi-asserted-by":"crossref","first-page":"11679","DOI":"10.1182\/blood-2022-168052","article-title":"A phase II study of mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: updated results and predictors for outcomes","volume":"140","author":"Nasnas","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.09.008_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.09.008_bib0072","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.09.008_bib0073","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1182\/blood-2022-166035","article-title":"Fractionated inotuzumab ozogamicin combined with low-intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL): results of the EWALL-INO study","volume":"140","author":"Chevallier","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0074","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood-2023-190902","article-title":"Updated results from a phase II study of hyper-CVAD, with or without inotuzumab ozogamicin, and sequential blinatumomab in patients with newly diagnosed B-cell acute lymphoblastic leukemia","volume":"142","author":"Nguyen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0075","doi-asserted-by":"crossref","first-page":"8966","DOI":"10.1182\/blood-2022-157358","article-title":"The addition of inotuzumab ozogamicin to hyper-CVAD plus blinatumomab further improves outcomes in patients with newly diagnosed B-cell acute lymphobastic leukemia: updated results from a phase II study","volume":"140","author":"Short","year":"2022","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2025.09.008_bib0076","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0077","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2024-209438","article-title":"Addition of inotuzumab to a pediatric inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia: findings from the Alliance A041501 phase 3 randomized trial","volume":"144","author":"DeAngelo","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0078","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2021-149478","article-title":"A phase 3 randomized trial of inotuzumab ozogamicin for newly diagnosed high-risk B-ALL: a safety phase results from children's oncology group protocol AALL1732","volume":"131","author":"McNeer","year":"2021","journal-title":"Blood"},{"issue":"Suppl 16","key":"10.1016\/j.clml.2025.09.008_bib0079","article-title":"A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: second safety results from children\u2019s oncology group AALL1732","volume":"41","author":"O\u2019Brien","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.09.008_bib0080","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V91.11.3995","article-title":"Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia","volume":"91","author":"Faderl","year":"1998","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.09.008_bib0081","first-page":"3983","article-title":"Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia group B experience","volume":"93","author":"Wetzler","year":"1999","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.09.008_bib0082","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","article-title":"Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-from intensive chemotherapy combinations to chemotherapy-free regimens: a review","volume":"8","author":"Jabbour","year":"2022","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.09.008_bib0083","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","article-title":"Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2013results of the prospective multicenter LALA-94 trial","volume":"100","author":"Dombret","year":"2002","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2025.09.008_bib0084","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"Fielding","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.09.008_bib0085","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26816","article-title":"Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.clml.2025.09.008_bib0086","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Foa","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.09.008_bib0087","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the Dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Foa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.09.008_bib0088","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2023-180204","article-title":"Long-term follow up for SWOG 1318: combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia-chromosome (Ph) positive acute lymphoblastic leukemia","volume":"142","author":"Advani","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.09.008_bib0089","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani","year":"2023","journal-title":"Blood Adv"},{"issue":"36","key":"10.1016\/j.clml.2025.09.008_bib0090","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.09.008_bib0091","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjh.18537","article-title":"Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: a retrospective multicentre campus ALL study","volume":"200","author":"Dargenio","year":"2023","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.clml.2025.09.008_bib0092","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood.2022016194","article-title":"The role of allogeneic transplant for adult ph+ ALL in CR1 with complete molecular remission: a retrospective analysis","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0093","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1182\/blood-2023-189632","article-title":"Comparison between dasatinib-blinatumomab vs ponatinib-blinatumomab chemo-free strategy for newly diagnosed ph+ acute lymphoblastic leukemia patients. Preliminary results of the Gimema ALL2820 trial","volume":"142","author":"Chiaretti","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.09.008_bib0094","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/cncr.33321","article-title":"Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Stock","year":"2021","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2025.09.008_bib0095","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ajh.26238","article-title":"Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia","volume":"96","author":"Jain","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.008_bib0096","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.09.008_bib0097","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11864-020-00757-5","article-title":"Biology and treatment paradigms in T cell acute lymphoblastic leukemia in older adolescents and adults","volume":"21","author":"Patel","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.09.008_bib0098","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.09.008_bib0099","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.09.008_bib0100","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3324\/haematol.2023.283848","article-title":"Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia","volume":"109","author":"Oh","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2025.09.008_bib0101","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJM199902183400703","article-title":"Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency","volume":"340","author":"Buckley","year":"1999","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.clml.2025.09.008_bib0102","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.09.008_bib0103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1410519","article-title":"Acute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope","volume":"15","author":"Jing","year":"2024","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.clml.2025.09.008_bib0104","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2025.09.008_bib0105","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.2024024493","article-title":"Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study","volume":"144","author":"Bhatla","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.09.008_bib0106","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ajh.27094","article-title":"Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy","volume":"98","author":"Zhang","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.09.008_bib0107","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3892\/mmr.2024.13171","article-title":"CAR\u2011T cell therapy: a breakthrough in traditional cancer treatment strategies (Review)","volume":"29","author":"Sun","year":"2024","journal-title":"Mol Med Rep"},{"issue":"5","key":"10.1016\/j.clml.2025.09.008_bib0108","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"10299","key":"10.1016\/j.clml.2025.09.008_bib0109","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clml.2025.09.008_bib0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2025.09.008_bib0111","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2025.09.008_bib0112","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.09.008_bib0113","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2025.09.008_bib0114","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor Consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clml.2025.09.008_bib0115","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.008_bib0116","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-023-00813-x","article-title":"CD19\/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study","volume":"13","author":"Niu","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2025.09.008_bib0117","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2025.0674","article-title":"Dasatinib and CAR T-cell therapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a nonrandomized clinical trial","volume":"11","author":"Zhang","year":"2025","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.008_bib0118","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clinthera.2023.10.020","article-title":"Health care resource utilization and total costs of care for adult patients with relapsed or refractory acute lymphoblastic leukemia in the United States: a retrospective claims analysis","volume":"46","author":"Ito","year":"2024","journal-title":"Clin Ther"},{"key":"10.1016\/j.clml.2025.09.008_bib0119","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood-2022-162235","article-title":"Inotuzumab ozogamicin induction followed by standard chemotherapy yields high remission rates and promising survival in older (<55 years) patients with de novo B-lymphoblastic Leukemia (GMALL- Initial Trial)","volume":"140","author":"Stelljes","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.008_bib0120","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/blood-2021-145529","article-title":"A phase 2 study of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia- chromosome (Ph) positive or ph-like acute lymphoblastic leukemia (ALL) (with dasatinib sensitive fusions\/mutations)","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:17:42Z","timestamp":1770650262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":120,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2152265025042016"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Incorporating Immunotherapy into Upfront Acute Lymphoblastic Leukemia Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}